Scientific
Advisory Board

 

Zhengrong (Rong) Cui
Zhengrong (Rong) Cui is a Professor and Alfred and Dorothy Mannino Fellow in Pharmacy at The University of Texas at Austin (UT Austin), College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery. He is also a member of the LIVESTRONG Cancer Institutes at UT Austin Dell Medical School. His research interests lie in drug and vaccine delivery and experimental tumor therapy. He has nearly twenty years of experience in using pharmaceutical chemistry and nanotechnology to overcome tumor resistance to (chemo)therapy, to target anti-inflammatory agents to chronic inflammation sites, and to improve the immunogenicity of vaccine antigens. He published extensively in the fields of pharmaceutics and vaccinology, including numerous peer-reviewed research papers, review papers, and book chapters. He is an inventor on several patents and patent applications that cover antitumor compounds, nucleic acid delivery systems, vaccine adjuvants, and dry powder vaccines. He teaches Biopharmaceutics to professional Doctor of Pharmacy students and Advanced Biopharmaceutics to graduate students. Dr. Cui serves as an editor of the research journal International Journal of Pharmaceutics. He holds a Ph.D. degree in Pharmaceutical Sciences from the University of Kentucky and completed his postdoctoral training at the University of Pittsburgh.

Scott Tagawa
Scott T. Tagawa, MD, MS is an Associate Professor in Hematology and Oncology, an Associate Professor of Clinical Medicine & Urology at Weill Cornell Medicine, and an Associate Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center.

After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine. After completing his Internship and Residency training there, he became Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years. He had the opportunity to train with international leaders in Genitourinary (GU) Oncology. In August 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medical College in 2007. His research covers clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer. Dr. Tagawa also serves as Associate Director of Clinical Research for the Division of Hematology and Medical Oncology, Medical Director of the Cancer Clinical Trials Office of the Meyer Cancer Center, and Chair of the Clinical Study Evaluation (scientific review) Committee for cancer. He was promoted to Associate Professor of Clinical Medicine and Urology in 2013. Dr. Tagawa is the WCMC principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. He is a member of the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology (ASCO). Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple “top doctor” award lists.

Rana Quraishi, Ph.D.
Rana Quraishi, Ph.D. has spent much of her career working in life science directed finance, investment and consulting organizations. At the TCG Group, a premiere private equity firm she focused on business development opportunities for its life science companies. Prior to this she was a Principal at Conning Capital Partners/SwissRe an early stage private equity fund providing growth capital for entrepreneurial companies where she served on Boards of several portfolio companies. She was also a member of the startup team for Helicon Therapeutics, a biotech company with assets contributed by Cold Spring Harbor and OSI Pharmaceuticals. She developed the Company’s business plan, and made investor presentations leading to $6 million in initial funding. Helicon was subsequently acquired. Earlier in her career Rana worked for Standard and Poor’s, GE Capital where she was Commercial Quality Leader for GE Capital and prior to that headed the Business Development Group at its FGIC subsidiary, J.E. Seagram and American Express where she led treasury and acquisitions and divestitures groups. She has served on several for-profit and not for-profit boards, and also wrote the widely read “Market Demand Study for Commercial Biotechnology, Biomedical, and Bioinformatics Facilities in New York City” for the New York City Partnership and Investment Fund. Dr. Quraishi has a PhD in Molecular Biology and Biochemistry from Columbia University where she was also an undergraduate and an MS degree from Harvard University.

GET

Email Alerts.

Receive the latest news & events.